Zoetis Inc

ZTS-N

Get Alerts37 watching

NYSE:ZTS

114.61
1.42 (1.22%)
Zoetis, Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of ...
More at Wikipedia
ZTS Fundamental Data  by TradingView
ZTS Chart  by TradingView
Technical Analysis for ZTS  by TradingView

Analysis and Opinions about ZTS-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
March 12, 2020
(A Top Pick May 21/19, Up 18%) Pharma company for animals, livestock and pets. Great story. Great company and an opportunity to do well.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
March 12, 2020
(A Top Pick May 21/19, Up 18%) Pharma company for animals, livestock and pets. Great story. Great company and an opportunity to do well.
Consumer Products
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$120.280
Owned
Yes
BUY
BUY
Zoetis Inc (ZTS-N)
January 8, 2020
The pet medicine industry continues to grow. There are few competitors. He's recommended ZTS many times before. People spend $3K on their pets. ZTS has pricing power.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
January 8, 2020
The pet medicine industry continues to grow. There are few competitors. He's recommended ZTS many times before. People spend $3K on their pets. ZTS has pricing power.
Consumer Products
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$133.290
Owned
Yes
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
December 19, 2019
They make drugs for pets. $6.2 billion was spent in 2001 on pets and now it's over $15 billion. Each owner spend $3,000 on their pet, mostly out of pocket. The process to get a pet drug to market is faster than a drug for humans. Lots of growth. (Analysts’ price target is $135.31)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 19, 2019
They make drugs for pets. $6.2 billion was spent in 2001 on pets and now it's over $15 billion. Each owner spend $3,000 on their pet, mostly out of pocket. The process to get a pet drug to market is faster than a drug for humans. Lots of growth. (Analysts’ price target is $135.31)
Consumer Products
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$128.740
Owned
Yes
BUY
BUY
Zoetis Inc (ZTS-N)
December 2, 2019
The companion animal market has grown very strongly in the developed world. This company has less exposure to livestock. They provide testing services to vets. He likes the company. He likes the long term prospects of the company but banks will do better if interest rates keep going up.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 2, 2019
The companion animal market has grown very strongly in the developed world. This company has less exposure to livestock. They provide testing services to vets. He likes the company. He likes the long term prospects of the company but banks will do better if interest rates keep going up.
Consumer Products
0 Comments
David Fingold

Unlock Ratings

Price
$119.910
Owned
No
COMMENT
COMMENT
Zoetis Inc (ZTS-N)
November 8, 2019
They make pharmaceuticals for pets. The action today looks like it’s breaking down. The volume looks good but there’s been a lot of selling. He would be very cautious.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
November 8, 2019
They make pharmaceuticals for pets. The action today looks like it’s breaking down. The volume looks good but there’s been a lot of selling. He would be very cautious.
Consumer Products
0 Comments
Jeff Parent B. Eng. FCSI CIM

Unlock Ratings

Price
$117.860
Owned
No
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
October 24, 2019
(A Top Pick Nov 07/18, Up 30%) Revenue split between pet care and livestock. Owners are increasingly willing to spend money on pets. Fragmented industry. Huge margins. 20 consecutive quarters of positive earnings surprises. Good name long-term. Bit pricey, but they can catch up.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 24, 2019
(A Top Pick Nov 07/18, Up 30%) Revenue split between pet care and livestock. Owners are increasingly willing to spend money on pets. Fragmented industry. Huge margins. 20 consecutive quarters of positive earnings surprises. Good name long-term. Bit pricey, but they can catch up.
Consumer Products
0 Comments
Stan Wong

Unlock Ratings

Price
$0.000
Owned
Yes
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
October 18, 2019
The biggest livestock and pet medicine maker in the world. They have 300 R&D projects in the works. A solid long term uptrend in place. A recent technical buy signal has him thinking now is the time to buy. Yield 0.51% (Analysts’ price target is $132.00)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 18, 2019
The biggest livestock and pet medicine maker in the world. They have 300 R&D projects in the works. A solid long term uptrend in place. A recent technical buy signal has him thinking now is the time to buy. Yield 0.51% (Analysts’ price target is $132.00)
Consumer Products
0 Comments
Hap (Robert) Sneddon FCSI

Unlock Ratings

Price
$128.120
Owned
Yes
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
September 26, 2019
People spend over $15 billion for over-the-counter drugs for their pets. There are no generic ones that compete and it's easier to bring to market (less testing) compared to meds for humans. (Analysts’ price target is $128.86)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
September 26, 2019
People spend over $15 billion for over-the-counter drugs for their pets. There are no generic ones that compete and it's easier to bring to market (less testing) compared to meds for humans. (Analysts’ price target is $128.86)
Consumer Products
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$126.060
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
September 11, 2019
(A Top Pick Sep 12/18, Up 37%) Healthcare for animals. 33x earnings. Industry is a high-margin business. Consumer doesn't have much pricing power. Greater global need for healthier livestock. Reported 20 consecutive quarters of positive earnings.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
September 11, 2019
(A Top Pick Sep 12/18, Up 37%) Healthcare for animals. 33x earnings. Industry is a high-margin business. Consumer doesn't have much pricing power. Greater global need for healthier livestock. Reported 20 consecutive quarters of positive earnings.
Consumer Products
0 Comments
Stan Wong

Unlock Ratings

Price
$120.700
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
August 2, 2019
(A Top Pick Aug 20/18, Up 26%) Lumped into the same sector as drugs for humans. So, because this sector has been under pressure from political rhetoric, ZTS's stock price is lower than it should be. ZTS continues to do well in the livestock space due to Asian swine flu.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
August 2, 2019
(A Top Pick Aug 20/18, Up 26%) Lumped into the same sector as drugs for humans. So, because this sector has been under pressure from political rhetoric, ZTS's stock price is lower than it should be. ZTS continues to do well in the livestock space due to Asian swine flu.
Consumer Products
0 Comments
David Fingold

Unlock Ratings

Price
$115.860
Owned
Yes
BUY
BUY
Zoetis Inc (ZTS-N)
July 2, 2019
It's an animal healthcare company, both livestock and pets. Livestock growns along with GDP; as populations become urbanized, families consume more protein. Pets are a great growth business. There's little competition in this space to supply generic drugs for pets, and more and more people are buying pets. Owners spend $3,000 a year to maintain a pet.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
July 2, 2019
It's an animal healthcare company, both livestock and pets. Livestock growns along with GDP; as populations become urbanized, families consume more protein. Pets are a great growth business. There's little competition in this space to supply generic drugs for pets, and more and more people are buying pets. Owners spend $3,000 a year to maintain a pet.
Consumer Products
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$114.590
Owned
Yes
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
May 21, 2019
Animal healthcare company. Spun out of Pfizer in 2013. From 2001 to 2018, spending on animal healthcare went from $6.2B to $15.5B. Young people all have pets. One of the great thing is that a lot of the costs are out of the pocket, not many insurances companies in the market. Not a lot of generics that compete with the drugs, and getting new drugs approved for animals is faster. Very little debt. Good growth perspective. (Analysts’ price target is $106.33)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
May 21, 2019
Animal healthcare company. Spun out of Pfizer in 2013. From 2001 to 2018, spending on animal healthcare went from $6.2B to $15.5B. Young people all have pets. One of the great thing is that a lot of the costs are out of the pocket, not many insurances companies in the market. Not a lot of generics that compete with the drugs, and getting new drugs approved for animals is faster. Very little debt. Good growth perspective. (Analysts’ price target is $106.33)
Consumer Products
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$102.380
Owned
Yes
BUY
BUY
Zoetis Inc (ZTS-N)
December 27, 2018
It was too cheap because the whole pharma industry was out of favor. This whole industry is not out of favor from politicians. This has a better balance sheet, margins, and manufacturing costs. He continues to see it doing well unless something impacts livestock herds or companion animal populations.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 27, 2018
It was too cheap because the whole pharma industry was out of favor. This whole industry is not out of favor from politicians. This has a better balance sheet, margins, and manufacturing costs. He continues to see it doing well unless something impacts livestock herds or companion animal populations.
Consumer Products
0 Comments
David Fingold

Unlock Ratings

Price
$84.330
Owned
Yes
COMMENT
COMMENT
Zoetis Inc (ZTS-N)
December 3, 2018
They've been hitting it out of the park and continues to see great topline growth. He sold it because Eli Lilly spun out their business into Elanco, the #2 in animal health. There's a premium valuation on ZTS, because there's little else to get exposure to animal health. At 27x earnings, this will get hit more in a pullback.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 3, 2018
They've been hitting it out of the park and continues to see great topline growth. He sold it because Eli Lilly spun out their business into Elanco, the #2 in animal health. There's a premium valuation on ZTS, because there's little else to get exposure to animal health. At 27x earnings, this will get hit more in a pullback.
Consumer Products
0 Comments
Paul MacDonald

Unlock Ratings

Price
$93.570
Owned
No
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
November 7, 2018
Big producer of medicine and vaccines for livestock and pets, with revenues roughly evenly split between those two areas. Living standards are rising in developing countries, so they need vaccines for healthy livestock. Also, pet owners will pay well (vaccines) to heal their pets. (Analysts’ price target is $98.91)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
November 7, 2018
Big producer of medicine and vaccines for livestock and pets, with revenues roughly evenly split between those two areas. Living standards are rising in developing countries, so they need vaccines for healthy livestock. Also, pet owners will pay well (vaccines) to heal their pets. (Analysts’ price target is $98.91)
Consumer Products
0 Comments
Stan Wong

Unlock Ratings

Price
$95.190
Owned
Yes
Showing 1 to 15 of 23 entries
Next Page

Zoetis Inc(ZTS-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Zoetis Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Zoetis Inc(ZTS-N) Frequently Asked Questions

What is Zoetis Inc stock symbol?

Zoetis Inc is a American stock, trading under the symbol ZTS-N on the New York Stock Exchange (ZTS). It is usually referred to as NYSE:ZTS or ZTS-N

Is Zoetis Inc a buy or a sell?

In the last year, 7 stock analysts published opinions about ZTS-N. 7 analysts recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Zoetis Inc.

Is Zoetis Inc a good investment or a top pick?

Zoetis Inc was recommended as a Top Pick by Paul Harris, CFA on 2020-03-12. Read the latest stock experts ratings for Zoetis Inc.

Why is Zoetis Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Zoetis Inc worth watching?

7 stock analysts on Stockchase covered Zoetis Inc In the last year. It is a trending stock that is worth watching.

What is Zoetis Inc stock price?

On 2020-04-03, Zoetis Inc (ZTS-N) stock closed at a price of $114.61.

© Stockchase Inc.